Corcept Therapeutics Incorporated
$ 36.48
3.23%
24 Feb - close price
- Market Cap 3,723,837,000 USD
- Current Price $ 36.48
- High / Low $ 37.58 / 35.40
- Stock P/E 40.62
- Book Value 6.01
- EPS 0.87
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.17 %
- 52 Week High 117.33
- 52 Week Low 28.66
About
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Analyst Target Price
$76.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-04 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0 | 0.16 | 0.29 | 0.1693 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 | 0.14 |
| Estimated EPS | 0.254 | 0.13 | 0.1864 | 0.1425 | 0.4233 | 0.28 | 0.23 | 0.22 | 0.26 | 0.22 | 0.15 | 0.19 |
| Surprise | -0.254 | 0.03 | 0.1036 | 0.0268 | -0.1633 | 0.13 | 0.09 | 0.03 | 0.02 | 0.06 | 0.1 | -0.05 |
| Surprise Percentage | -100% | 23.0769% | 55.5794% | 18.807% | -38.5778% | 46.4286% | 39.1304% | 13.6364% | 7.6923% | 27.2727% | 66.6667% | -26.3158% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2026-02-24 13:52:03
Kirby McInerney LLP has filed a securities class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ:CORT) on behalf of investors who purchased securities between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for its drug relacorilant, leading to a significant stock price decline after the FDA issued a Complete Response Letter for its New Drug Application. Investors who suffered losses are encouraged to contact the firm by April 21, 2026, to request lead plaintiff appointment.
2026-02-24 13:34:03
Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics Inc. (NASDAQ: CORT) on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misled investors by claiming its lead product, relacorilant, was backed by "powerful evidence" and "approaching approval," while the FDA had reportedly issued repeated warnings about insufficient clinical data. The stock plunged over 50% after Corcept revealed a Complete Response Letter from the FDA on December 31, 2025, confirming the agency's concerns about the drug's effectiveness.
2026-02-24 01:52:03
Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for investors who purchased stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misrepresented clinical trial data for relacorilant, leading to investor losses, including a significant stock price drop after the FDA issued a Complete Response Letter on December 31, 2025. Investors wishing to serve as lead plaintiffs must file with the court by April 21, 2026.
2026-02-24 00:52:04
Kahn Swick & Foti, LLC (KSF) has initiated a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) following a significant 50% drop in its stock price. This decline occurred after the FDA issued a Complete Response Letter for Corcept's new drug candidate, relacorilant, indicating a lack of sufficient evidence of effectiveness. Investors who purchased Corcept shares between October 31, 2024, and December 30, 2025, are encouraged to contact KSF to discuss their legal rights and potentially serve as a lead plaintiff by April 21, 2026.
2026-02-23 21:47:08
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (NASDAQ: CORT) for potential securities violations. This investigation follows a significant stock price decline after the FDA issued a Complete Response Letter for Corcept's relacorilant NDA, citing insufficient evidence of effectiveness and previous concerns about its clinical development program. Investors who suffered losses are being encouraged to contact Kaplan Fox for more information.
2026-02-23 21:04:43
The Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misrepresented the strength of clinical trial support for their new drug application and the status of FDA communications, leading investors to suffer damages when the true details emerged. Stockholders are urged to contact the firm by April 21, 2026, to learn about their rights or to serve as lead plaintiff.
